Author is bullish on ImmunityBio, citing FDA regulatory discussions for ANKTIVA in bladder cancer and existing approvals in Saudi Arabia and the UK.
IBRX — LONG Author argues ImmunityBio's ANKTIVA is the only medicine treating BCG-unresponsive papillary bladder cancer that also treats with or without tumors, and the company is in advanced talks with the US FDA on a potential resubmission path. Existing approvals in Saudi Arabia and the UK support the regulatory narrative. The author's conclusion is to buy and hold, implying a positive view on approval-driven upside.
Currently in advanced talks with US FDA. Already approved in Saudi Arabia. Already approved in UK
List goes on and on
Buy and hold